Skip to main content

Advertisement

Table 1 Comparison of RECIST version 1.1 and the Choi criteria

From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

  RECIST version 1.1 Choi criteria
CR Disappearance of all lesions No new lesions Disappearance of all lesions No new lesions
PR A decrease in sizea of ≥30% A decrease in sizea of ≥10% or a decrease in tumor density (HU) of ≥15% in CT No new lesions No obvious progression of immeasurable disease
SD Neither sufficient shrinkage to qualify for PR nor a sufficient increase to qualify for PD Does not meet the criteria for CR, PR, or PD No symptomatic deterioration attributable to tumor progression
PD An increase in sizea of ≥20% New lesions New intratumoral nodules or increase in the size of the existing intratumoral nodules An increase in tumor sizea of ≥10% and does not meet the criteria for PR based on tumor density (HU) in CT New lesions New intratumoral nodules or an increase in the size of the existing intratumoral nodules
  1. aSum of the diameters of the target lesions defined in RECIST version 1.1 [20]